

## THURSDAY SEPTEMBER 27<sup>th</sup>

### 09.00 - 11.00 hs. - Opening Session

09.00 - 09.15 hs. - Welcome

*Hernán Trimarchi*

09:15 - 10.00 hs. - IgA nephropathy - A 50 year perspective

*John Feehally*

### 10.00 - 11.00 hs. - The Omics revolution and IgAN

*(Chairs: Jonathan Barratt & Ali Gharavi)*

10.00 - 10:30 hs. - Genomics and transcriptomics

*Krystoff Kyriluk*

10:30 - 11.00 hs. - Proteomics & glycomics

*Matthew B. Renfrow*

### 11.00 - 11.30 hs. - Coffee break and poster viewing

### 11.30 - 13.30 hs. - Pathology

*(Chairs: Rosanna Coppo & Daniel Cattran)*

11.30 - 12.00 hs. - The Oxford classification. Novel aspects and future trends

*Ian Roberts*

12.00 - 12.30 hs. - The S score: Is there evidence for a podocytopathy in IgAN?

*Terry Cook*

12.30 - 13.00 hs. - Vascular lesions in IgAN: Any place?

*Mark Haas*

13.00 - 13.30 hs. - Free communications

### 13.30 - 14.30 hs. - Lunch

### 14.30 - 17.30 hs. - Hot topics in IgAN

*(Chairs: Heather Reich & Tetsuya Kawamura)*

14.30 - 15.00 hs. - Can we use IgA1 immune complexes to select therapeutic targets in IgAN?

*Jan Novak*

15.00 - 15.30 hs. - Can biomarkers help in the diagnosis and management of IgAN?

*Hitoshi Suzuki*

15.30 - 16.00 hs. - Should the Oxford score be used to guide treatment decisions in IgAN?

*Zhi-Hong Liu*


### 16.00 - 16.30 hs. - Coffee break

16.30 - 17.00 hs. - The social media revolution: integration into research and patient education

*Mathew Graham Brown*

17.00 - 17.30 hs. - Free communications

### 19.00 hs. - Dinner and Tango show on site



## FRIDAY SEPTEMBER 28<sup>th</sup>

### 09.00 - 11.00 hs. - Treatment controversies in IgAN

*(Chairs: Sean Barbour & Hernán Trimarchi)*

09.00 - 09.15 hs. - *Steroids* are a valuable treatment option in IgAN  
*Vladimir Tesar*

09.15 - 09.30 hs. - *Steroids* have no place in the treatment of IgAN  
*Hernán Trimarchi*

09.30 - 09.40 hs. - Discussion and audience vote

09.40 - 09.55 hs. - *Mycophenolate*: Short term therapy in IgAN. A valid option?  
*Hong Zhang*

09.55 - 10.10 hs. - *Mycophenolate*: Short term therapy in IgAN. Not a valid option?  
*Daniel Cattran*

10.10 - 10.20 hs. - Discussion and audience vote

10.20 - 10.35 hs. - *Tonsillectomy* is a valuable treatment option in IgAN  
*Tetsuya Kawamura*

10.35 - 10.50 hs. - *Tonsillectomy* has no place in the treatment of IgAN  
*John Feehally*

10.50 - 11.00 hs. - Discussion and audience vote

### 11.00 - 11.25 hs. - Coffee break

### 11.25 - 13.15 hs. - How do you design a clinical trial in IgAN?

*(Chairs: John Feehally & Yusuke Suzuki)*

11.25 - 11.45 hs. - Controversies in IgAN-the KDIGO perspective  
*Sean Barbour*

11.45 - 12.15 hs. - What does the perfect IgAN clinical trial look like?  
*Kevin Carroll*

12.15 - 12.45 hs. - What does the FDA look for when reviewing a clinical trial protocol?  
*Aliza Thompson*


12.45 - 13.15 hs. - The Kidney Health Initiative and IgAN  
*Patrick Nachman*

### 13.15 - 14.15 hs. - Lunch

### 14.15 - 16.45 hs. - Pathogenesis

*(Chairs: Zhi-Hong Liu & Terry Cook)*

14.15 - 14.45 hs. - The intestinal-renal axis in the pathogenesis of IgA nephropathy: does it play a role?  
*Loreto Gesualdo*



14.45 - 15.15 hs. - Role of intestinal microbiota dysbiosis in IgA nephropathy: from patients to humanized mouse models?

*Renato Monteiro*

15.15 - 15.45 hs. - Is IgAN in childhood the same as adult IgAN?


*Rosanna Coppo*

15.45 - 16.15 hs. - How can we translate what we know about IgAN to IgA Vasculitis (HSP)?

*Evangeline Pillebout*

16.15 - 16.45 hs. - Free communications

**19.00 hs. - Dinner on site**



## SATURDAY SEPTEMBER 29<sup>th</sup>

### 09.00 - 11.30 hs. - From bench to bedside

*(Chairs: Jan Novak & Hitoshi Suzuki)*

09.00 - 09.30 hs. - Modulating the mucosal immune system-is it the future in IgAN?

*Jonathan Barratt*

09.30 - 10.00 hs. - B cells in IgAN and the rationale for B cell directed therapies in IgAN

*Yusuke Suzuki*

10.00 - 10.30 hs. - Could complement inhibition be useful in IgA nephropathy?

*Moh Daha*

10.30 - 11.00 hs. - Tyrosine kinase inhibition from cell culture to clinical trial

*Fred Tam*

11.00 - 11.30 hs. - Free communications

### 11.30 - 12.00 hs. - Coffee break

### 12.00 - 14.00 hs. - For the future

*(Chairs: Hong Zhang & Bruce Julian)*

12.00 - 12.30 hs. - How will genomics alter how we approach IgAN in the next decade?

*Ali Gharavi*

12.30 - 13.00 hs. - Personalised risk stratification in IgAN-is it possible?

*Sean Barbour*

13.00 - 13.30 hs. - A new global IgAN cohort-what does this mean for the IlgANN?

*Heather Reich*

### 13.30 - 14.00 hs. - Awarding of the Berger Prize

*Renato Monteiro*

### Concluding remarks

*Renato Monteiro*

### Farewell

*Hernán Trimarchi*

### 14.00 - 15.00 hs. - Lunch and departures

